title: Atrial fibrillation in the heart failure population.
abstract: Atrial fibrillation (AF) is the most common chronic arrhythmia. Incidence of AF in the heart failure population is high--10% to 30%--and is associated with a reduction in exercise capacity and a poor long-term prognosis. Management of AF includes 4 strategies: control of heart rate, termination of AF/conversion back to sinus rhythm, prevention of recurrences, and prevention of thromboembolic events. This article reviews these management strategies in the heart failure population.
authors.affiliation: Cardiology, Kaiser Permanente Mid-Atlantic States, Washington, DC, USA. carol.a.offutt@kp.org
authors.forename: Carol
authors.initials: C
authors.lastname: Offutt
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D017115:Catheter Ablation; D002908:Chronic Disease; D004554:Electric Countershock; D017079:Exercise Tolerance; D006333:Heart Failure / Q000150:complications*; D006339:Heart Rate; D006801:Humans; D015994:Incidence; D010627:Phenethylamines / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002301:Cardiac Glycosides; D002316:Cardiotonic Agents; D010627:Phenethylamines; D013449:Sulfonamides; D000638:Amiodarone; C063533:dofetilide